Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New portable device could speed up asthma diagnosis

NCT ID NCT07516184

Diagnosis Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 4 times

Summary

This study aims to see if a portable device that measures lung function can accurately diagnose asthma in people with symptoms like wheezing or coughing. Researchers will compare this new test to the standard breathing tests currently used. The study plans to enroll 500 adults across 25 sites in China.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all the following criteria and sign an informed consent form (ICF) to be eligible for the study. 1. Patient must be aged 18-75 years old at the time of enrollment. 2. Presented with asthmatic symptoms such as wheezing, shortness of breath, chest tightness and cough ≥2 months prior to enrollment (Day 0), with/without an established asthma diagnosis. Exclusion Criteria: Patients are excluded from the study if any of the following criteria apply: Medical Conditions 1. Respiratory infections within 3 months prior to enrollment (Day 0), including but not limited to: acute bacterial/viral pneumonia, acute bronchitis, Influenza, COVID-19 or acute exacerbation of chronic bronchitis. 2. Current smoker; or cessation from smoking less than 6 months; or cessation smoking for more than 6 months but smoked more than 10 packs/year. 3. History of other chronic respiratory diseases other than asthma, including but not limited to tuberculosis, significant bronchiectasis, established interstitial lung disease, and lung cancer. 4. History of serious comorbidities, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could: 1. Affect the safety of the patient throughout the study, 2. Confound the study results or impact the scientific validity of the data outcome, 3. Impede the patient's ability to complete the entire duration of study. 5. Positive urine pregnancy test, or breastfeeding women, or any women who are planning to become pregnant (current and within 3 months). Prior/Concomitant Therapy 6. ICS-based medication (including ICS, ICS/LABA, ICS/LABA/LAMA) use within 3 months prior to enrollment (Day 0). ICS=inhaled corticosteroids; LABA=long-acting β2 agonists; LAMA=long-acting muscarinic antagonists. Other Exclusions 7. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 8. Current participation in another interventional clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Suspected asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Suspected asthma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    25 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Beijing, 100000, China

  • Research Site

    NOT_YET_RECRUITING

    Cangzhou, 061000, China

  • Research Site

    NOT_YET_RECRUITING

    Changsha, 410008, China

  • Research Site

    RECRUITING

    Changsha, 430033, China

  • Research Site

    NOT_YET_RECRUITING

    Chengdu, 610041, China

  • Research Site

    NOT_YET_RECRUITING

    Chongqing, 400016, China

  • Research Site

    RECRUITING

    Guangzhou, 510000, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, 510000, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, 510120, China

  • Research Site

    RECRUITING

    Guangzhou, 510630, China

  • Research Site

    NOT_YET_RECRUITING

    Kunming, 650032, China

  • Research Site

    RECRUITING

    Quanzhou, 362000, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, 200032, China

  • Research Site

    RECRUITING

    Shanghai, 200065, China

  • Research Site

    RECRUITING

    Shanghai, 200080, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, 200433, China

  • Research Site

    NOT_YET_RECRUITING

    Suzhou, 215006, China

  • Research Site

    RECRUITING

    Taiyuan, 030001, China

  • Research Site

    NOT_YET_RECRUITING

    Tianjin, 300192, China

  • Research Site

    RECRUITING

    Ürümqi, 830054, China

  • Research Site

    RECRUITING

    Wuhan, 430048, China

  • Research Site

    NOT_YET_RECRUITING

    Xi'an, 710004, China

  • Research Site

    NOT_YET_RECRUITING

    Yangzhou, 225001, China

  • Research Site

    RECRUITING

    Zhengzhou, 450000, China

  • Research Site

    RECRUITING

    Zhuhai, 519000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.